These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1087 related items for PubMed ID: 35590083

  • 21. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A, McCourt PM, Karachunski P, Lowe DA, Ervasti JM.
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [Abstract] [Full Text] [Related]

  • 22. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
    Eren SA, Tastan C, Karadeniz KB, Turan RD, Cakirsoy D, Kancagi DD, Yilmaz SU, Oztatlici M, Oztatlici H, Ozer S, Tumentemur G, Baykal AT, Ovali E.
    Curr Gene Ther; 2023 Dec; 23(4):304-315. PubMed ID: 37032509
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy.
    Siemionow M, Ziemiecka A, Bożyk K, Siemionow K.
    Biomedicines; 2024 Sep 02; 12(9):. PubMed ID: 39335509
    [Abstract] [Full Text] [Related]

  • 25. Electrical impedance myography detects dystrophin-related muscle changes in mdx mice.
    Hiyoshi T, Zhao F, Baba R, Hirakawa T, Kuboki R, Suzuki K, Tomimatsu Y, O'Donnell P, Han S, Zach N, Nakashima M.
    Skelet Muscle; 2023 Nov 18; 13(1):19. PubMed ID: 37980539
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
    Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, Lefebvre A, Shugay M, Tong J, Vaudry D, Arkle S, doRego JC, Górecki DC.
    PLoS Med; 2015 Oct 18; 12(10):e1001888. PubMed ID: 26461208
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts.
    Iyer PS, Mavoungou LO, Ronzoni F, Zemla J, Schmid-Siegert E, Antonini S, Neff LA, Dorchies OM, Jaconi M, Lekka M, Messina G, Mermod N.
    Mol Ther; 2018 Apr 04; 26(4):1093-1108. PubMed ID: 29503200
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 55.